Bio-Path Holdings (BPTH) – Globe Newswire
-
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
-
Bio-Path Holdings Expands Global Patent Portfolio
-
Bio-Path Holdings Provides 2024 Clinical and Operational Update
-
Bio-Path Holdings Reports Full Year 2023 Financial Results
-
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
-
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
-
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patie
-
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
-
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
-
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
-
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
-
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
-
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
-
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
-
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
-
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
-
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
-
Bio-Path Holdings Reports First Quarter 2023 Financial Results
-
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
-
Bio-Path Holdings Reports Full Year 2022 Financial Results
-
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
-
Bio-Path Holdings Provides Clinical and Operational Update
-
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
-
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
-
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
-
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
-
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
-
Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Bio-Path Holdings Reports Second Quarter 2022 Financial Results
-
Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022
-
Bio-Path Holdings Reports First Quarter 2022 Financial Results
-
Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022
-
Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting
-
Bio-Path Holdings Appoints Aline Sherwood to Board of Directors
-
Bio-Path Holdings Reports Full Year 2021 Financial Results
-
Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting
-
Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
-
Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
-
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
-
Bio-Path Holdings Reports Third Quarter 2021 Financial Results
-
Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021
-
Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
-
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
-
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
-
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
-
Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021
-
Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003
-
Bio-Path Holdings Reports First Quarter 2021 Financial Results
Back to BPTH Stock Lookup
